Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02813694 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
A Phase 3 study of Community-acquired Pneumonia, sponsored by Nabriva Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 738
- Enrollment target
- 20
- Study locations
NCT02813694: Completed Phase 3 study of Community-acquired Pneumonia, sponsored by Nabriva Therapeutics.
NCT02813694 is a Phase 3 study of Community-acquired Pneumonia that has completed, run by Nabriva Therapeutics. The registered enrollment target is 738 participants, below the 109,039-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02813694, a Phase 3 study of Community-acquired Pneumonia, has completed, sponsored by Nabriva Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 738 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
Primary Outcome
ECR was defined as survival with improvement in at least 2 signs and symptoms of CABP (relative to baseline), no worsening of any CABP sign or symptom, and no use of concomitant antibiotics for the treatment of CABP through the ECR assessment
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG lefamulin
Study Locations (20)
California
- 1080 - Beverly Hills
- Site 1065 - Fresno
- 1078 - Northridge
- Site 1072 - Oxnard
- Site 1070 - Sacramento
- 1079 - Sherman Oaks
- Site 1053 - Sylmar
Florida
- Site 1064 - DeBary
- Site 1052 - DeLand
- 1076 - Miami
Michigan
- Site 1055 - Detroit
- Site 1062 - Detroit
- Site 1068 - Royal Oak
Indiana
- Site 1051 - Michigan City
Louisiana
- Site 1057 - Natchitoches
Massachusetts
- Site 1073 - New Bedford
Missouri
- Site 1058 - St Louis
Montana
- Site 1054 - Butte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
What the finished NCT02813694 record still lists
NCT02813694 is an interventional study that assigns participants to a tested intervention. The registered 738 participants enrollment target is mid-sized for trials with a published cap, below the 109,039-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Community-acquired Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which Moxifloxacin is the first listed.
NCT02813694 names 20 study sites across 10 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02813694 about?
NCT02813694 is a clinical study titled "Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia". This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
What is the current status of trial NCT02813694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 738 participants. The study started on 2016-08. Estimated completion is 2018-01.
What conditions does trial NCT02813694 study?
This clinical trial studies the following conditions: Community-acquired Pneumonia.
What interventions are being tested in trial NCT02813694?
The interventions under investigation include: Moxifloxacin (DRUG), lefamulin (DRUG).
Who is sponsoring clinical trial NCT02813694?
This trial is sponsored by Nabriva Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02813694 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Community-acquired Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02813694's enrollment target sits among peer trials
738 7th of 9 higher than 3 of 9 other Community-acquired Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Community-acquired Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
RECRUITING · Phase 3
-
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
RECRUITING · Phase 3
-
Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia
RECRUITING · NA
-
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
RECRUITING · Phase 4
-
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
RECRUITING
-
Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia